Rifapentine/Isoniazid 300/300 Adco 300 mg, 300 mg FC tablets
PDF Leaflet Revision Date: 25 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of active tuberculosis in high-risk patients with latent tuberculosis infection.
Dosage (summary)
Once-weekly for 12 weeks; adults: rifapentine 900 mg, isoniazid 15 mg/kg; children: rifapentine based on weight, isoniazid 25 mg/kg.
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential harm.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Antiretroviral therapy
- Hormonal contraceptives
Contraindications
- Hypersensitivity to rifapentine or isoniazid
- Acute or chronic liver disease
- Severe renal failure
- Alcoholism
- Uncontrolled seizures
Common side effects
- Hypersensitivity
- Hepatitis
- Nausea
- Headache
Counselling Points
- Take with food
- Avoid tyramine-rich foods
- Monitor for liver function
- Report any skin reactions immediately
Serious warnings
- Hepatotoxicity
- Severe cutaneous adverse reactions
- Clostridium difficile-associated diarrhoea
Important Disclaimer
The Rifapentine/Isoniazid 300/300 Adco 300 mg, 300 mg FC tablets professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
